Back

Systemic tumor-targeting gene drive vectors proactively eliminate drug resistance in solid tumors

Leighow, S. M.; Hemann, M.; Pritchard, J. R.

2025-10-05 bioengineering
10.1101/2025.10.04.680477 bioRxiv
Show abstract

While targeted therapies have revolutionized cancer treatment, drug resistance remains a major barrier to their curative potential. We recently demonstrated biological proof-of-concept for selection gene drive circuits, a technology that overwrites disease evolution to proactively eliminate resistance in vivo, but translation requires a delivery method compatible with disseminated metastatic disease. Now, we demonstrate a clinically feasible delivery solution with novel tumor-targeting lentiviral vectors that selectively install these therapeutic circuits in tumor cells in situ. Systemic administration of these vectors demonstrated durable elimination of visible tumor burden and minimal body weight loss, validating the translational potential of a new class of genetic medicines for long-term control of resistance in cancer.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Nature Biomedical Engineering
○ 47 papers in training set
Top 0.1%
15.0%
Similar papers in this journal
2
Molecular Therapy
○ 81 papers in training set
Top 0.1%
11.8%
Similar papers in this journal
3
Nature Communications
○ 5641 papers in training set
Top 17%
10.9%
Similar papers in this journal
4
Science Advances
● 1243 papers in training set
Top 4%
5.4%
Similar papers in this journal
5
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 10%
5.1%
Similar papers in this journal
6
ACS Central Science
● 71 papers in training set
Top 0.2%
4.3%
50% of probability mass above
7
Nature Biotechnology
○ 172 papers in training set
Top 0.9%
4.3%
8
Science Translational Medicine
● 127 papers in training set
Top 0.7%
3.2%
9
Bioengineering & Translational Medicine
○ 21 papers in training set
Top 0.1%
3.1%
10
Cancer Research
● 130 papers in training set
Top 1%
2.8%
11
Cell Reports Medicine
○ 153 papers in training set
Top 2%
2.1%
12
npj Precision Oncology
○ 53 papers in training set
Top 0.8%
1.9%
13
Cellular and Molecular Bioengineering
○ 22 papers in training set
Top 0.2%
1.7%
14
Nature Medicine
○ 125 papers in training set
Top 2%
1.7%
15
Cancer Cell
○ 42 papers in training set
Top 0.9%
1.4%
16
Journal for ImmunoTherapy of Cancer
● 75 papers in training set
Top 1%
1.4%
17
Molecular Therapy - Methods & Clinical Development
○ 38 papers in training set
Top 0.4%
1.3%
18
Neuro-Oncology Advances
◐ 25 papers in training set
Top 0.3%
1.1%
19
Cell Chemical Biology
○ 94 papers in training set
Top 1%
1.1%
20
eLife
● 5828 papers in training set
Top 59%
1.1%
21
Molecular Cancer Therapeutics
● 40 papers in training set
Top 0.7%
1.0%
22
Signal Transduction and Targeted Therapy
○ 30 papers in training set
Top 0.5%
1.0%
23
Blood
● 74 papers in training set
Top 1%
0.8%
24
Molecular Therapy Nucleic Acids
○ 39 papers in training set
Top 0.9%
0.8%
25
Bioconjugate Chemistry
● 20 papers in training set
Top 0.3%
0.8%
26
Nature Cancer
○ 39 papers in training set
Top 2%
0.6%
27
mAbs
○ 32 papers in training set
Top 0.5%
0.6%
28
Scientific Reports
○ 3612 papers in training set
Top 77%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.